Darwin Wealth Management’s Vaxcyte PCVX Stock Holding History

Darwin Wealth Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$174	Buy	+3	New	+$175	﹤0.01%	1109

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Darwin Wealth Management's PCVX Position: Q3 2026 in Review

Darwin Wealth Management opened a new position in Vaxcyte (PCVX) in Q3 2026: 3 shares worth $174. The stake represents ﹤0.01% of the portfolio and ranks #1109 among its holdings.

167 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

Darwin Wealth Management held 3 shares of Vaxcyte worth $174 as of Q3 2026.
Vaxcyte was a new Darwin Wealth Management position in Q3 2026.
Vaxcyte made up ﹤0.01% of Darwin Wealth Management's portfolio in Q3 2026, its #1109 holding.
167 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Darwin Wealth Management's 13F filing for Q3 2026, filed 9 Nov 2026.